Chronic elevation of plasma fibroblast growth factor 19 in long‐term farnesoid X receptor agonist therapy, a happy marriage or cause for oncological concern?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|67|2|782-784

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.67, Iss.2, 2018-02, pp. : 782-784

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 2, 2018-02 ,pp. : 342-349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell Carcinoma

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 321-331

Karger

Access to resources Recommend Favorite

Role of the fibroblast growth factor receptor axis in cholangiocarcinoma

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1116-1122

John Wiley & Sons Inc

Access to resources Recommend Favorite

Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 10, 2013-11 ,pp. : 1320-1321

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C

By  

Oncology, Vol. 72, Iss. 1, 2007-12 ,pp. : 16-23

Karger

Access to resources Recommend Favorite